Nanoparticle vaccine based on the envelope protein domain III of Japanese encephalitis virus elicits robust protective immune responses in mice

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3(1), 13–22 (2005).
  Medline CASGoogle Scholar
• 2. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol. 267, 171–194 (2002).
  Medline CASGoogle Scholar
• 3. Turtle L, Solomon T. Japanese encephalitis – the prospects for new treatments. Nat. Rev. Neurol. 14(5), 298–313 (2018).
  MedlineGoogle Scholar
• 4. Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol. Rev. 14, 197–221 (1992).
  Medline CASGoogle Scholar
• 5. Li MH, Fu SH, Chen WX et al. Genotype v Japanese encephalitis virus is emerging. PLOS Negl. Trop. Dis. 5(7), e1231 (2011).
  MedlineGoogle Scholar
• 6. Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol. 77(5), 3091–3098 (2003).
  Medline CASGoogle Scholar
• 7. Tsarev SA, Sanders ML, Vaughn DW, Innis BL. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18(Suppl. 2), 36–43 (2000).
  Medline CASGoogle Scholar
• 8. Hashimoto H, Nomoto A, Watanabe K et al. Molecular cloning and complete nucleotide sequence of the genome of Japanese encephalitis virus Beijing-1 strain. Virus Genes 1(3), 305–317 (1988).
  Medline CASGoogle Scholar
• 9. Sumiyoshi H, Mori C, Fuke I et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161(2), 497–510 (1987).
  Medline CASGoogle Scholar
• 10. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229(4715), 726–733 (1985).
  Medline CASGoogle Scholar
• 11. Kim JK, Kim JM, Song BH et al. Profiling of viral proteins expressed from the genomic RNA of Japanese encephalitis virus using a panel of 15 region-specific polyclonal rabbit antisera: implications for viral gene expression. PLOS ONE 10(4), e0124318 (2015).
  MedlineGoogle Scholar
• 12. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44, 649–688 (1990).
  Medline CASGoogle Scholar
• 13. Zhang W, Chipman PR, Corver J et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nature Struct. Biol. 10(11), 907–912 (2003).
  Medline CASGoogle Scholar
• 14. Lorenz IC, Allison SL, Heinz FX, Helenius A. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J. Virol. 76(11), 5480–5491 (2002).
  Medline CASGoogle Scholar
• 15. McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. J. Gen. Virol. 78(Pt 11), 2711–2722 (1997).
  Medline CASGoogle Scholar
• 16. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375(6529), 291–298 (1995).
  Medline CASGoogle Scholar
• 17. Luca VC, Abimansour J, Nelson CA, Fremont DH. Crystal structure of the Japanese encephalitis virus envelope protein. J. Virol. 86(4), 2337–2346 (2012).
  Medline CASGoogle Scholar
• 18. Lin CW, Wu SC. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J. Virol. 77(4), 2600–2606 (2003). • Elucidated the detailed molecular structures of the neutralizing epitope determinants on Japanese encephalitis virus (JEV) envelope protein domain III, which can provide useful information for designing JEV vaccines.
  Medline CASGoogle Scholar
• 19. Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21(25–26), 3675–3683 (2003).
  Medline CASGoogle Scholar
• 20. Saini M, Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol. 77(6), 3487–3494 (2003). • Developed a virus-like particle vaccine by fusing JEV neutralization epitopes to Johnson grass mosaic virus coat protein by recombinant DNA methods. The recombinant particles containing JEV peptide sequences induced anti-peptide and anti-JEV antibodies. This study provided insight for our research.
  Medline CASGoogle Scholar
• 21. Konishi E, Yamaoka M, Kurane I, Mason PW. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine. Virology 268(1), 49–55 (2000).
  Medline CASGoogle Scholar
• 22. Baharuddin A, Hassan AA, Sheng GC et al. Current approaches in antiviral drug discovery against the Flaviviridae family. Curr. Pharm. Des. 20(21), 3428–3444 (2014).
  Medline CASGoogle Scholar
• 23. Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum. Vaccin. Immunother. 10(2), 263–279 (2014).
  Medline CASGoogle Scholar
• 24. Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J. Trop. Med. Public Health 26(4), 689–693 (1995).
  Medline CASGoogle Scholar
• 25. Ku CC, King CC, Lin CY et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J. Med. Virol. 44(2), 122–131 (1994).
  Medline CASGoogle Scholar
• 26. Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb. Mortal. Wkly Rep. 60(20), 661–663 (2011).
  MedlineGoogle Scholar
• 27. Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28(21), 3635–3641 (2010).
  Medline CASGoogle Scholar
• 28. Monath TP, Arroyo J, Levenbook I et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76(4), 1932–1943 (2002).
  Medline CASGoogle Scholar
• 29. Yang D, Li XF, Ye Q et al. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine 32(23), 2675–2681 (2014).
  Medline CASGoogle Scholar
• 30. Andersen MM, Rønne T. Side-effects with Japanese encephalitis vaccine. Lancet 337(8748), 1044 (1991).
  Medline CASGoogle Scholar
• 31. Plesner AM, Arlien-Søborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348(9021), 202–203 (1996).
  Medline CASGoogle Scholar
• 32. Kanekiyo M, Wei CJ, Yassine HM et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499(7456), 102–106 (2013). •• Developed an influenza nanoparticle vaccine by genetically fusing virus haemagglutinin to ferritin. This structure-based, self-assembling synthetic nanoparticle vaccine improves the potency and breadth of influenza virus immunity and provides a foundation for vaccine design based on self-assembled nanoparticles.
  Medline CASGoogle Scholar
• 33. Tokatlian T, Read BJ. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science 363(6427), 649–654 (2019). •• The authors identified a novel innate immune-mediated recognition pathway promoting humoral immunity to particulate antigens, with broad implications for humoral immunity to microbes and the design of improved vaccines.
  Medline CASGoogle Scholar
• 34. Schiller JT, Lowy DR. Papillomavirus-like particle vaccines. J. Natl Cancer Inst. Monogr. a024258(28), 50–54 (2001).
  Google Scholar
• 35. Wei Y, Kumar P, Wahome N, Mantis NJ, Middaugh CR. Biomedical applications of lumazine synthase. J. Pharm. Sci. 107(9), 2283–2296 (2018). • Review focusing on the applications of lumazine synthase (LS) as a flexible vaccine presentation system. Presentation of antigens on the surface of LS results in a high local concentration of antigens displayed in an ordered array. This study provided the idea for a JEV nanoparticle design based on LS.
  Medline CASGoogle Scholar
• 36. Jardine J, Julien JP, Menis S et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340(6133), 711–716 (2013). •• The authors developed a germline-targeting HIV immunogen by fusing gp120 outer domain immunogen on LS nanoparticles, a method which could be applied to other epitopes and pathogens.
  Medline CASGoogle Scholar
• 37. Ra JS, Shin HH. Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development. Clin. Exp. Vaccine Res. 3(2), 227–234 (2014).
  Medline CASGoogle Scholar
• 38. Liu W, Sohn HW, Tolar P, Pierce SK. It’s all about change: the antigen-driven initiation of B-cell receptor signaling. Cold Spring Harb. Perspect. Biol. 2(7), a002295 (2010).
  MedlineGoogle Scholar
• 39. Baschong W, Hasler L, Häner M, Kistler J, Aebi U. Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity. J. Struct. Biol. 143(3), 258–262 (2003).
  Medline CASGoogle Scholar
• 40. Zhang X, Meining W, Fischer M, Bacher A, Ladenstein R. X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile Aquifex aeolicus at 1.6 A resolution: determinants of thermostability revealed from structural comparisons. J. Mol. Biol. 306(5), 1099–1114 (2001).
  Medline CASGoogle Scholar
• 41. Azuma Y, Zschoche R, Hilvert D. The C-terminal peptide of Aquifex aeolicus riboflavin synthase directs encapsulation of native and foreign guests by a cage-forming lumazine synthase. J. Biol. Chem. 292(25), 10321–10327 (2017).
  Medline CASGoogle Scholar
• 42. Tian M, Cheng C, Chen X et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 166(6), 1471–1484.e1418 (2016).
  Medline CASGoogle Scholar
• 43. Jardine JG, Ota T, Sok D et al. HIV-1 vaccines. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349(6244), 156–161 (2015).
  Medline CASGoogle Scholar
• 44. Zhang H, Wen W, Zhao Z et al. Enhanced protective immunity to CSFV E2 subunit vaccine by using IFN-γ as immunoadjuvant in weaning piglets. Vaccine 36(48), 7353–7360 (2018).
  Medline CASGoogle Scholar
• 45. Sasaki E, Böhringer D, Van De Waterbeemd M et al. Structure and assembly of scalable porous protein cages. Nat. Commun. 8, 14663 (2017).
  MedlineGoogle Scholar
• 46. Gao N, Li J, Sheng Z et al. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice. Appl. Microbiol. Biotechnol. 103(12), 4977–4986 (2019).
  Medline CASGoogle Scholar
• 47. Chen Y, Hu Y, Chen H, Li X, Qian P. A ferritin nanoparticle vaccine for foot-and-mouth disease virus elicited partial protection in mice. Vaccine 38(35), 5647–5652 (2020). •• The authors developed a ferritin nanoparticle vaccine by fusing foot-and-mouth disease virus antigens to a ferritin scaffold, which elicited effective immune responses in mice. This research provided the insight for nanoparticle vaccine design based on a ferritin scaffold.
  Medline CASGoogle Scholar
• 48. Campbell GL, Hills SL, Fischer M et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89(10), 766–774 (2011).
  MedlineGoogle Scholar
• 49. Mansfield KL, Hernández-Triana LM, Banyard AC, Fooks AR, Johnson N. Japanese encephalitis virus infection, diagnosis and control in domestic animals. Vet. Microbiol. 201, 85–92 (2017).
  MedlineGoogle Scholar
• 50. Kumar A, Sharma P, Shukla KK, Misra S, Nyati KK. Japanese encephalitis virus: associated immune response and recent progress in vaccine development. Microb. Pathog. 136, 103678 (2019).
  Medline CASGoogle Scholar
• 51. Zheng X, Zheng H, Tong W et al. Acidity/alkalinity of Japanese encephalitis virus E protein residue 138 alters neurovirulence in mice. J. Virol. 92(22), e00108–18 (2018).
  MedlineGoogle Scholar
• 52. Nath B, Vandna, Saini HM, Prasad M, Kumar S. Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice. Vaccine 38(7), 1860–1868 (2020).
  Medline CASGoogle Scholar
• 53. Zheng X, Yu X, Wang Y, Cui M, Wang R, Yin C. Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain. Infect. Genet. Evol. 85, 104443 (2020).
  Medline CASGoogle Scholar
• 54. Kumar K, Ong HK, Tan WS. Immunological analysis of Nodavirus capsid displaying the domain III of Japanese encephalitis virus envelope protein. Pharmaceutics 13(11), 1826 (2021). • The authors developed a JEV nanoparticle vaccine by fusing JEV envelope protein domain III to a capsid protein, which assembled into a virus-like particle vaccine with good immunogenicity. This study offered ideas for the design of a JEV nanoparticle vaccine.
  Medline CASGoogle Scholar
• 55. Chen T, Zhu S, Wei N et al. Protective immune responses induced by an mRNA–LNP vaccine encoding prM-E proteins against Japanese encephalitis virus infection. Viruses 14(6), 1121 (2022).
  Medline CASGoogle Scholar
• 56. Geng Q, Tai W, Baxter VK. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLOS Pathog. 17(9), e1009897 (2021).
  Medline CASGoogle Scholar
• 57. Wang W, Liu Z, Zhou X et al. Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy. Nanomedicine 16, 69–78 (2019).
  Medline CASGoogle Scholar
• 58. Pabisch S, Feichtenschlager B, Kickelbick G, Peterlik H. Effect of interparticle interactions on size determination of zirconia and silica based systems – a comparison of SAXS, DLS, BET, XRD and TEM. Chem. Phys. Lett. 521(C), 91–97 (2012).
  Medline CASGoogle Scholar
• 59. Eaton P, Quaresma P, Soares C et al. A direct comparison of experimental methods to measure dimensions of synthetic nanoparticles. Ultramicroscopy 182, 179–190 (2017).
  Medline CASGoogle Scholar